Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.2701
At close: Jun 23 EDT
$0.2882
0.026.70%
Pre-Market: 4:01 AM EDT
Comments
Loading...
Indaptus Therapeutics Analyst Ratings and Price Targets | NASDAQ:INDP | Benzinga
Indaptus Therapeutics Inc has a consensus price target of $8.5 based on the ratings of 2 analysts. The high is $12 issued by HC Wainwright & Co. on October 16, 2024. The low is $5 issued by Maxim Group on November 13, 2024. The 3 most-recent analyst ratings were released by Maxim Group, HC Wainwright & Co., and HC Wainwright & Co. on November 13, 2024, October 16, 2024, and June 17, 2024, respectively. With an average price target of $9.67 between Maxim Group, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 3254.15% upside for Indaptus Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Maxim Group
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Indaptus Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 11/13/2024 | Buy Now | 1634.91% | Maxim Group | Jason McCarthy42% | $8 → $5 | Maintains | Buy | Get Alert |
| 10/16/2024 | Buy Now | 4063.78% | HC Wainwright & Co. | Raghuram Selvaraju44% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 06/17/2024 | Buy Now | 4063.78% | HC Wainwright & Co. | Raghuram Selvaraju44% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 04/15/2024 | Buy Now | 4063.78% | HC Wainwright & Co. | Raghuram Selvaraju44% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 09/20/2023 | Buy Now | 4063.78% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $12 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2023 | Buy Now | 4063.78% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $12 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | Buy Now | 4063.78% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $12 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | Buy Now | 4063.78% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $12 | Reiterates | Buy → Buy | Get Alert |
| 05/04/2023 | Buy Now | 4063.78% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $12 | Reiterates | → Buy | Get Alert |
| 03/20/2023 | Buy Now | 4063.78% | HC Wainwright & Co. | Raghuram Selvaraju44% | $15 → $12 | Maintains | Buy | Get Alert |
| 03/08/2023 | Buy Now | 5104.72% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $15 | Reiterates | → Overweight | Get Alert |
| 02/08/2023 | Buy Now | 5104.72% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $15 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for Indaptus Therapeutics (INDP) stock?
The latest price target for Indaptus Therapeutics (NASDAQ:INDP) was reported by Maxim Group on November 13, 2024. The analyst firm set a price target for $5.00 expecting INDP to rise to within 12 months (a possible 1634.91% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Indaptus Therapeutics (INDP)?
The latest analyst rating for Indaptus Therapeutics (NASDAQ:INDP) was provided by Maxim Group, and Indaptus Therapeutics maintained their buy rating.
When was the last upgrade for Indaptus Therapeutics (INDP)?
There is no last upgrade for Indaptus Therapeutics
When was the last downgrade for Indaptus Therapeutics (INDP)?
There is no last downgrade for Indaptus Therapeutics.
When is the next analyst rating going to be posted or updated for Indaptus Therapeutics (INDP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Indaptus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Indaptus Therapeutics was filed on November 13, 2024 so you should expect the next rating to be made available sometime around November 13, 2025.
Is the Analyst Rating Indaptus Therapeutics (INDP) correct?
While ratings are subjective and will change, the latest Indaptus Therapeutics (INDP) rating was a maintained with a price target of $8.00 to $5.00. The current price Indaptus Therapeutics (INDP) is trading at is $0.29, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
